Search results

• Responsible business

  /Images/Corporate/Corporate V2/Sustainability/Our commitment sustainability image

• Coltide Radiance sustainability in use

  In October we were delighted that our sustainability leadership was recognised as we won Business of the Year at the World Sustainability Awards.

• Share price

  Detailed share charts.

• Waste management

  Iberchem, our global fragrance and flavours business based in Spain, has championed waste management best practices through robust policies and employee education programmes.

• Agroforestry in the Amazon

  The Croda Foundation is supporting an Instituto Amazonas agroforestry project, which aims to revive traditional agriculture practices among indigenous tribes, improving food security and protecting their cultural heritage and environment.

• Shareholder centre

  Useful information for Croda Shareholders.

• Supplying delivery systems to help prevent cardiovascular disease

  Nucleic acid-based therapies are the next big blockbuster drug class opening up exciting applications such as gene editing, where a patient’s genetic material can be modified to correct a disorder.

• Supporting the next generation of therapeutic vaccines

  Vaccine adjuvants are used to enhance immune response to an antigen, improving the overall efficacy of the vaccine and increasing protection against the target disease.

• Bringing anti-ageing benefits to make-up

  Developed through one of our Smart Partnerships, Majestem® Drypure™ from our beauty actives business, Sederma, brings anti-ageing and environmental protection benefits to make-up.

• Sustainability-linked revolving credit facility

  In 2019, we became one of the UK’s first large public companies to include a sustainability metric in a revolving credit facility (RCF), with targets in the seven-year agreement aligned with our 2030 Commitment to become Climate Positive.

• Collaboration to develop alternative vaccine adjuvants

  In 2021 we established a strategic collaboration with the Danish Government’s life science research institute, Statens Serum Institute (SSI).

• Investors

  Investor information including financial reporting and events.

• Finance review 2025

  “With a comprehensive transformation programme that is driving both growth and efficiencies, we are firmly focused on execution. Progress so far has been encouraging, and we are setting out a financial framework to full year 2028 that outlines further improvements in financial performance.”

• Life Sciences business review - rebalancing Pharma and driving differentiation in Agriculture

  Discover how Life Sciences is rebalancing Pharma and driving differentiation in Agriculture. Exploring innovation, market trends, and strategic growth driving performance in this year’s annual report business review.

• Industrial Specialties business review

  Discover how Industrial Specialties is enabling continued growth, exploring innovation, market trends, and strategic growth driving performance in this year’s annual report business review.

• Consumer Care business review

  Discover how Consumer Care is reinvigorating Beauty and enabling continued growth in Fragrances & Flavours. Exploring innovation, market trends, and strategic growth driving performance in this year’s annual report business review.

• Croda unveils Matrixyl® Neolide™, an iconic peptide with smarter delivery

  Croda introduces Matrixyl® Neolide™, an iconic peptide with smarter delivery, designed to maximise performance and unlock new possibilities in advanced skin care.

• Investor seminar on our Life Sciences sector

  7 October 2019: Senior members of our management team provided a comprehensive overview of the Life Sciences sector, with a particular focus on our Health Care business.

• Site visit to Sederma Beauty Actives business in France

  17-18 March 2016: Croda International plc hosted a Capital Markets Event for analysts and investors at its Sederma facility near Versailles, France.

• Chairs statement 2025

  A message from the Chair, Danuta Gray, highlighting the company’s performance, strategic progress, governance priorities, and outlook for sustainable growth in the year ahead.